Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study.
Sign Up to like & getrecommendations! Published in 2023 at "European journal of cancer"
DOI: 10.2139/ssrn.4329566
Abstract: BACKGROUND This multicenter phase 2 trial evaluated the safety and efficacy of osimertinib and platinum-based chemotherapy (OPP) in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer (NSCLC). PATIENTS AND METHODS Patients received… read more here.
Keywords: untreated egfr; previously untreated; mutated advanced; advanced non ... See more keywords